Status:

COMPLETED

Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors

Lead Sponsor:

Michigan State University

Collaborating Sponsors:

National Institute of Nursing Research (NINR)

Conditions:

Breast Cancer

Eligibility:

FEMALE

21+ years

Phase:

NA

Brief Summary

This study will implement therapeutic bright light that is tailored to the individual's circadian typology and will estimate its effects on circadian rhythms, 4 common cancer-associated symptoms, and ...

Detailed Description

The purpose of this pilot study is to evaluate the feasibility of implementing a home-based, personalized bright light intervention, and to estimate the effects of bright light on 4 common long-term o...

Eligibility Criteria

Inclusion

  • Females
  • 21 years of age or older 1-3 years post-completion of chemotherapy or/and radiation therapy for stage I-III breast cancer
  • Experience ≥ 2 concurrent symptoms (fatigue, sleep disruption, depressive symptoms, and/or cognitive dysfunction as measured by 4 screening instruments)
  • Be either phase advanced or delayed (morning or evening types by the Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ) ≥59 or ≤41)
  • Sighted
  • Mentally competent to consent
  • Able to understand English.

Exclusion

  • Undergoing cancer treatment for another malignancy
  • Have metastatic cancer
  • Engaged in shift work or travel across more than three time zones within 2 weeks prior to study
  • Current diagnosis of seasonal affective disorder or substance abuse Current diagnosis of major Axis I psychiatric disorders (e.g. depressive disorders), neurological impairments, or muscular dystrophies
  • Report severe depressive mood (Center for Epidemiological Studies Depression Scale (CES-D) \>24)
  • Take prescribed sedative hypnotics or steroids Have eye conditions (glaucoma or retinal disease), problems triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)

Key Trial Info

Start Date :

November 6 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2022

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03304587

Start Date

November 6 2017

End Date

August 31 2022

Last Update

June 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Michigan State University

East Lansing, Michigan, United States, 48824